Blue Earth Diagnostics

Company snapshot

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company’s success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positr

• 11 active pipeline program(s) linked via ClinicalTrials.gov.
• 11 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Blue Earth Diagnostics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Blue Earth Diagnostics.

1. Jun 8, 2026 Clinical update

   BS-03 — Phase 1

2. Jun 8, 2026 Clinical update

   BS-02 — Phase 1

3. Jun 8, 2026 Clinical update

   BET-PSMA-001 — Phase 1

4. Jun 8, 2026 Clinical update

   Lutetium (177Lu) rhPSMA-10.1 injection — Phase 2

5. Jun 5, 2026 Clinical update

   Placebo, BFB759 — Phase 2

View all clinical trial activity →

• What is Blue Earth Diagnostics?

  Blue Earth Diagnostics is a pharma organization headquartered in GB. Primary therapeutic focus areas include Chronic Hepatitis D Infection, Chronic Hepatitis Delta Infection, PSMA-positive non-curative metastatic castration-resistant prostate cancer, Metastatic castration-resista

• Is Blue Earth Diagnostics publicly traded?

  Blue Earth Diagnostics appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Blue Earth Diagnostics develop or market?

  We link 12 drug profile(s) where Blue Earth Diagnostics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/blue-earth-diagnostics-ireland-ltd#company-drugs.

• What are the latest developments for Blue Earth Diagnostics?

  In the last 12 months our linked public records show 11 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Blue Earth Diagnostics focus on?

  Blue Earth Diagnostics focuses on Chronic Hepatitis D Infection, Chronic Hepatitis Delta Infection, PSMA-positive non-curative metastatic castration-resistant prostate cancer based on our analysis of their pipeline programs and drug development activities.